id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1692-0007,FDA,FDA-2013-E-1692,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-02T23:50:22Z,,0,0,090000648214fd35
FDA-2013-E-1692-0006,FDA,FDA-2013-E-1692,"Determination of Regulatory Review Period for Purposes of Patent
Extension; KADCYLA",Notice,Determinations,2015-12-28T05:00:00Z,2015,12,2015-12-28T05:00:00Z,2016-02-27T04:59:59Z,2015-12-28T14:36:14Z,2015-32475,0,0,0900006481dd3c17
FDA-2013-E-1692-0005,FDA,FDA-2013-E-1692,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-12T05:00:00Z,2015,11,2015-11-12T05:00:00Z,,2015-11-12T13:35:50Z,,0,0,0900006481d38678
FDA-2013-E-1692-0004,FDA,FDA-2013-E-1692,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-25T04:00:00Z,2015,3,2015-03-25T04:00:00Z,,2015-03-25T16:27:59Z,,0,0,0900006481a64534
FDA-2013-E-1692-0003,FDA,FDA-2013-E-1692,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-27T04:00:00Z,2014,5,2014-05-27T04:00:00Z,,2014-05-27T15:45:19Z,,0,0,0900006481715d4e
FDA-2013-E-1692-0001,FDA,FDA-2013-E-1692,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T14:45:07Z,,0,0,09000064814dc7ee
FDA-2013-E-1692-0002,FDA,FDA-2013-E-1692,"Morrison & Foerster LLP (on behalf of Genenetech, Inc) - Patent Term Application",Other,Application,2013-12-26T05:00:00Z,2013,12,2013-12-26T05:00:00Z,,2013-12-26T14:45:22Z,,0,0,09000064814dc7ed